Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28,027,744
-
Total 13F shares
-
17,959,308
-
Share change
-
+3,412,833
-
Total reported value
-
$179,779,328
-
Put/Call ratio
-
285%
-
Price per share
-
$10.01
-
Number of holders
-
91
-
Value change
-
+$33,903,656
-
Number of buys
-
43
-
Number of sells
-
43
Institutional Holders of NextCure, Inc. - Common Stock (NXTC) as of Q1 2021
As of 31 Mar 2021,
NextCure, Inc. - Common Stock (NXTC) was held by
91 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,959,308 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Sofinnova Investments, Inc., BlackRock Inc., CITADEL ADVISORS LLC, MORGAN STANLEY, VANGUARD GROUP INC, Canaan Partners X LLC, HILLHOUSE CAPITAL ADVISORS, LTD., Ikarian Capital, LLC, and Voya Investment Management LLC.
This page lists
91
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.